Comparing ways to use pulsed field ablation for persistent atrial fibrillation
Compares pulsed field ablation approaches in people with persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Pulsed Field Ablation in Three Different Substrate Ablation Strategies for Persistent Atrial Fibrillation
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with persistent atrial fibrillation who did not respond to, or could not tolerate, at least one rhythm medicine.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Persistent atrial fibrillation.
- Earlier treatment
- At least one Class I or III anti-arrhythmic drug that did not work or was not tolerated.
Main reasons for not taking part
- Major valve disease that needs surgery
- Blood clot in the left atrium on recent imaging
- Recent heart attack
- Severe heart failure (LVEF ≤ 30%)
- Current severe infection
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06739512, who can take part
Where in China
- No. 241, West Huaihai RoadShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Chest Hospital
- Trial code
- NCT06739512
- Record updated
- 18 December 2024
- Original description
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of pulsed field ablation (PFA) in patients with persistent atrial fibrillation (PeAF). We will compare three distinct substrate ablation strategies: anatomical guided ablation (ANAT group), electrogram guided ablation (EGM group), and extensive electro-anatomical guided ablation (EXT group). The study seeks to identify which ablation strategy yields the highest efficacy and safety profiles to potentially guide future clinical practice in the management of PeAF.Read full original descriptionShow less
Efficacy and Safety of Pulsed Field Ablation in Three Different Substrate Ablation Strategies for Persistent Atrial Fibrillation: a Multicenter Randomized Controlled Trial
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of pulsed field ablation (PFA) in patients with persistent atrial fibrillation (PeAF). We will compare three distinct substrate ablation strategies: anatomical guided ablation (ANAT group), electrogram guided ablation (EGM group), and extensive electro-anatomical guided ablation (EXT group). The study seeks to identify which ablation strategy yields the highest efficacy and safety profiles to potentially guide future clinical practice in the management of PeAF.
Inclusion: Adults aged 18-80 years diagnosed with persistent atrial fibrillation; Ineffectiveness or intolerance to at least one Class I or III anti-arrhythmic drug.
Exclusion: Major valvular diseases needing surgical intervention; Current Severe Infection; Recent myocardial infarction or severe heart failure (LVEF ≤ 30%); Presence of a left atrial thrombus on recent imaging.